Uganda

previous Print
HIV/AIDS Statistics for Uganda

Total population in thousands (2007): 30,884*
Number of people living with HIV (2007):  940,000*
Women aged 15 to 24 prevalence rate (2007):  3.9*
Men aged 15 to 24 prevalence rate (2007):  1.3*
Adults aged 15 and up living with HIV (2007): 810,000*
Women aged 15 and up living with HIV (2007): 480,000*
Deaths due to AIDS (2007):  77,000*
Estimated antiretroviral therapy coverage (Dec 2007): 33%†
Estimated number of pregnant women living with HIV (2007): 78,000†


Ongoing biomedical HIV prevention research trials in Uganda
Vaccines PrEP PrEP & Microbicides

Vaccines

Trial: RV262
Phase: I
Start Date: September 2010
Sponsor, funder, developer: NIAID
Total participants: 92
Vaccine(s): Prime: PENNVAX-G DNA (ENV & GAG) Administered by Intramuscular Biojector 2000 or CELLECTRA Intramuscular Electroporation Device Boost: MVA-CMDR (HIV-1 CM235 ENV/CM240 GAG/POL)
Clade: A, B, C, D, E

Back to Top ↑

Pre-Exposure Prophylaxis

Trial: Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples [PartnersPrEP]
Phase: III
Product Being Tested: Daily oral TDF and daily oral TDF/FTC
Sponsor, funder, developer, collaborator: Bill and Melinda Gates Foundation, Infectious Diseases Institute, Partners House-Infectious Disease Institute Ltd, The AIDS Support Organization, The AIDS Support Organization - Tororo Field Station, Kabwohe Clinical Research Center
Total participants: 4,700
Countries: Kenya, Uganda
Trial sites in Uganda: Jinja, Kampala, Mbale, Tororo, Bushenyi
Results expected: 2012
For more information: http://clinicaltrials.gov/ct2/show/NCT00557245
Back to Top ↑

PrEP & Microbicides

Trial: Vaginal and Oral Interventions to Control the Epidemic [VOICE (MTN-003)]
Phase: IIb
Product Being Tested: Daily oral TDF, daily oral TDF/FTC, daily topical tenofovir gel
Sponsor, funder, developer, collaborator: Microbicide Trials Network, Division of AIDS/National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institue of Mental Health ; Gilead, CONRAD
Total participants: 5,000
Countries: Malawi, South Africa, Uganda, Zimbabwe
Trial sites in Uganda: Kampala
Results expected: 2013
For more information: http://www.mtnstopshiv.org/news/studies/mtn003, http://www.mtnstopshiv.org/node/70


Trial: Adherence and pharmacokinetics study of oral and vaginal preparations of tenofovir [MTN-001]
Phase: II
Product Being Tested: Tenofovir gel, oral TDF
Sponsor, funder, developer, collaborator: Microbicide Trials Network, Division of AIDS/National Institute of Allergey and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institue of Mental Health, Gilead, CONRAD
Total participants: 144
Countries: South Africa, Uganda, United States
Trial sites in Uganda: Kampala
Results expected: 2010
For more information: , http://clinicaltrials.gov/ct2/show/NCT00592124?term=MTN-001&rank=1 http://www.mtnstopshiv.org/news/studies/mtn001
Back to Top ↑

*WHO, UNAIDS, and UNICEF. Epidemiological Fact Sheet on HIV and AIDS: Core data on epidemiological and response Uganda 2008 Update. 2008.
For more information: http://www.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_UG.pdf
† WHO, UNAIDS, and UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: Progress Report. 2008.
For more information: http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf